Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2025 Aug;59(8):703-713.
doi: 10.1177/10600280241305608. Epub 2025 Jan 12.

Evaluation of the Toxicity and Outcomes of the Combination of Midostaurin and CLAG-M in Patients With FLT3-Mutated Acute Myeloid Leukemia (AML): A Multicenter Retrospective Analysis

Ashley Chen  1 , Grace Baek  1 , Kathryn Russell  2 , Carole Shaw  2 , Megan Othus  3 , Jonathan Cohen  1 , Shannon Palmer  4 , Jack Rasmussen  4 , Joseph Bubalo  4 , Tenzin Tsomo  5 , Tenley Schwarz  5 , Swathi Namburi  5 , Anna Halpern  2
Affiliations
Multicenter Study

Evaluation of the Toxicity and Outcomes of the Combination of Midostaurin and CLAG-M in Patients With FLT3-Mutated Acute Myeloid Leukemia (AML): A Multicenter Retrospective Analysis

Ashley Chen et al. Ann Pharmacother. 2025 Aug.

Abstract

Background: Addition of midostaurin to standard "7+3" (cytarabine and anthracycline) significantly prolongs overall and event-free survival. At University of Washington/Fred Hutchinson Cancer Center (UW/FHCC), the standard regimen for newly diagnosed (ND) and relapsed/refractory (R/R) AML is cladribine, high-dose cytarabine, GCSF, and mitoxantrone (CLAG-M); midostaurin is added if FLT3-mutated. There is limited data on the use of FLT3-inhibitors with high-dose cytarabine regimens in AML.

Objective: This study aimed to evaluate the safety and efficacy of the combination of midostaurin with CLAG-M versus midostaurin plus 7+3 in FLT3-mutated AML patients.

Methods: This is a retrospective, multicenter review including FLT3-mutated AML patients undergoing (re)induction chemotherapy with either CLAG-M or 7+3 at UW/FHCC, Oregon Health & Science University, and Swedish Cancer Institute. The primary outcome was incidence of adverse events. Secondary outcomes included disease response per ELN2017 criteria and 28-day mortality. Excluded were patients on clinical trials or who started midostaurin 30 days after chemotherapy.

Results: Eighty patients treated from September 2016 to December 2023 were included; 36 patients received CLAG-M, and 44 patients 7+3. Baseline characteristics were similar across all institutions. Adverse event rates were similar between the 2 cohorts, except diarrhea and bleeding which were more common in the 7+3 cohort. The rate of complete remission (CR) plus CR with incomplete blood count recovery did not significantly differ between the 2 cohorts: CLAG-M, 86% versus 7+3, 70% (P = 0.11).Conclusion & relevance:The toxicity profile of CLAG-M combined with midostaurin is comparable with the combination of 7+3 with midostaurin, and induces high remissions rates in adults with FLT3-mutated AML.

Keywords: 7+3; AML; CLAG-M; FLT3.

PubMed Disclaimer

Conflict of interest statement

Declaration of Conflicting InterestsThe authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: GB: Honorarium for presentation from Postgraduate Healthcare Education, LLC (supported by educational grant from Bristol Myers Squibb). JB: Research funding from Angiocrine Bioscience. AC: Honorarium for presentation from Oncology Pharmacy Network. JC: Currently employed by Servier Pharmaceuticals. AH: Research funding from Jazz Pharmaceuticals, Imago Pharma, Bayer, Gilead/Forty Seven, Incyte, Karyopharm Therapeutics, Disk Medicine. Honoria for lectures/presentation from Curio sciences. Consulting with Agios, Abbive, and Notable labs. SN: Consulting or advisory role with Bristol Myers Squibb/Celgene/Juno, Janssen, Sanofi, Regeneron, ORIC Pharmaceuticals. Honoraria from Medscape. MO: Consulting or advisory role with GlycoMimetics, Cascadia Labs, Merck, Daiichi Sankyo, Biosight. Other relationships with Celgene, GlycoMimetics, Grifols.

Publication types

MeSH terms

LinkOut - more resources